Pharmaceuticals

A new strategic deal for the Lasix ONYU device aims to secure its key ingredient, transforming heart failure care from the hospital to the living room.

With $108M in new funding, Terremoto Biosciences advances a novel class of drugs designed to overcome the toxicities of past cancer treatments.

Following a major partnership, AST and Marchesini Group will showcase next-gen robotic filling and inspection tech, aiming to reshape sterile drug production.

With new top-tier executives, Danish biotech MinervaX is accelerating its quest to deliver the world's first vaccine against a leading cause of infant death.

As millions drive on common medications, a leading expert joins a national panel to address the silent, growing crisis on America's roadways.

With backing from AI leaders, Helical’s virtual lab aims to turn powerful models into reproducible drug discovery systems, tackling a key industry bottleneck.

Phase 3 data shows GTx-104 reduces key risks and improves outcomes for aSAH patients, positioning it as a potential new standard of care ahead of an FDA decision.

Biotech firm Genvor leverages its AI platform in a new partnership, aiming to fast-track novel peptides for anti-aging and weight loss to a booming market.

With its lead depression drug nearing Phase 3, AtaiBeckley faces investors to tackle the regulatory and commercial hurdles of psychedelic medicine.

Harrow partners with specialist LogiCare3PL for U.S. distribution, highlighting an industry shift towards agile, high-touch logistics for faster market access.

Eli Lilly acquires CrossBridge Bio for its innovative dual-payload ADC platform, signaling a major push into the next wave of targeted cancer treatments.

BioTesserae's BTC-001, a novel immunotherapy, proves safe in early trials, paving the way for more affordable and accessible treatment for dogs.

FDA approves the first generic of a vital nutrition drug, granting Apotex a 180-day exclusive edge and signaling major cost savings for healthcare.

Renaissance Pharma's Daretabart gains FDA support for high-risk neuroblastoma, accelerating its journey to patients and offering new hope against this rare disease.

A new report reveals a major gap in AI adoption as digital disruptors and generic GLP-1s force Canadian pharmacies to innovate or risk being left behind.

European non-profit ELRIG launches its first US conference, a free-to-attend event aiming to connect scientists and tackle intractable drug targets.

As the $525B cold chain market booms and regulations tighten, Circle Logistics is enhancing its services to offer shippers greater reliability and compliance.

A new once-daily pill for hypoparathyroidism begins human testing, promising to replace burdensome injections and transform patient care. Is this the future?

A new alliance aims to deliver nine vital rare disease therapies to Africa, tackling one of global health's most profound access challenges.

ANI Pharmaceuticals launches a generic version of Carbatrol, aiming for a slice of a $65M market and promising improved patient access for chronic conditions.